Related references
Note: Only part of the references are listed.Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Bowen Sun et al.
ONCOGENE (2020)
CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition
Martina S. J. McDermott et al.
CELLS (2020)
CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification
Jae Young Hur et al.
CELLULAR ONCOLOGY (2019)
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
Tianlu Huang et al.
CELL DEATH & DISEASE (2019)
THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism
Zhu-Jun Cheng et al.
ACTA PHARMACOLOGICA SINICA (2019)
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery
Robert P. Fisher
TRANSCRIPTION-AUSTIN (2019)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu et al.
CELL (2018)
Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066
Cong-Cong Cheng et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation
Uri Mbonye et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng et al.
ELIFE (2018)
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
A. Harrod et al.
ONCOGENE (2017)
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
Florencia Cayrol et al.
NATURE COMMUNICATIONS (2017)
Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer
Quyen Thu Bui et al.
CANCER LETTERS (2017)
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer
Hetal Patel et al.
CLINICAL CANCER RESEARCH (2016)
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Yubao Wang et al.
CELL (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer
Muralidharan Anbalagan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
In Vitro Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency
Tatjana Michel et al.
NUCLEIC ACID THERAPEUTICS (2015)
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
Xia Zhang et al.
SCIENTIFIC REPORTS (2015)
Breast Cancer: Epidemiology and Etiology
ZiQi Tao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
D. Zhao et al.
ONCOGENE (2015)
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Edmond Chipumuro et al.
CELL (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
Highlights of the Latest Advances in Research on CDK Inhibitors
Jonas Cicenas et al.
CANCERS (2014)
The CDK-activating kinase Cdk7 Taking yes for an answer
Miriam Merzel Schachter et al.
CELL CYCLE (2013)
Treatment of Estrogen Receptor-Positive Breast Cancer
F. Lumachi et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Tamoxifen resistance: From bench to bedside
Marjolein Droog et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression
Miriam Merzel Schachter et al.
MOLECULAR CELL (2013)
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
A. Ward et al.
ONCOGENE (2013)
Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
Ming Chen et al.
ONCOLOGY LETTERS (2013)
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
Henrik J. Johansson et al.
NATURE COMMUNICATIONS (2013)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer
Georgios P. Skliris et al.
ENDOCRINE-RELATED CANCER (2010)
TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II
Md. Sohail Akhtar et al.
MOLECULAR CELL (2009)
Cyclin-dependent kinases: a family portrait
Marcos Malumbres et al.
NATURE CELL BIOLOGY (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer
Maiea Chanrion et al.
CLINICAL CANCER RESEARCH (2008)
The CDK inhibitors: potential targets for therapeutic stem cell manipulations?
M. J. Boyer et al.
GENE THERAPY (2008)
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells
Stephane Larochelle et al.
MOLECULAR CELL (2007)
Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
N. Sarwar et al.
ENDOCRINE-RELATED CANCER (2006)
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-α responsive promoters
ASL Cheng et al.
MOLECULAR CELL (2006)
WNT/β-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells
J Hao et al.
DEVELOPMENTAL BIOLOGY (2006)
Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation
P Mezquita et al.
ONCOGENE (2005)
Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells
RL Kilker et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer
PN Span et al.
ONCOGENE (2003)
Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells
YC Liang et al.
BIOCHEMICAL PHARMACOLOGY (2003)
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
TA Baudino et al.
GENES & DEVELOPMENT (2002)
Molecular determinants for the tissue specificity of SERMs
YF Shang et al.
SCIENCE (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
